VE303 for Recurrent C. Difficile Infection

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Recruiting Phase 3 Interventional Study
Clostridium Difficile Clostridium Difficile Infections Clostridium Difficile Infection Recurrence Clostridioides Difficile Infection Clostridioides Difficile Infection Recurrence CDI C. Diff Infection Recurrent Clostridium Difficile Infection C.Difficile Diarrhea Diarrhea Infectious
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Prevention
Participants needed
852 (estimated)
Sponsor
Vedanta Biosciences, Inc. · Industry
Who this trial is looking for

This trial is looking for people who have had repeated C. difficile infections. Participants will receive either a study drug or a placebo after completing an antibiotic treatment for their infection.

Are You a Good Fit for This Trial?
Must be taking Standard of care antibiotic therapy for C. difficile
Must not be taking BezlotoxumabAntidiarrheal drugs
Rules you out Celiac diseaseInflammatory bowel diseaseShort gut

You may be able to join if

  • I am at least 12 years old
  • I have had a confirmed case of C. difficile infection
  • I have had at least one prior occurrence of C. difficile in the last 6 months
  • I am at least 75 years old with a confirmed case of C. difficile
  • I am 12 or older and have two risk factors specified by the study

You may not be able to join if

  • I have had chronic diarrhea unrelated to C. difficile in the past 3 months
  • I have toxic megacolon or small bowel obstruction
  • I have a history of specific bowel diseases or conditions
  • I received bezlotoxumab during my antibiotic treatment for C. difficile
  • I took antidiarrheal medications within 3 days before the study drug
  • I plan to take antibiotics for something other than C. difficile after joining the trial
  • I have low white blood cell counts as defined by the study

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria (For enrollment in Stage 1: recurrent CDI population): * Age ≥ 12 years where permitted, and ≥ 18 years in other locations, with a laboratory-confirmed qualifying episode of CDI and at least 1 prior occurrence within the last 6 months Key Inclusion Criteria (For enrollment i…
Contacts

Paul McGovern, MD

857-706-1427

Consortium02-ctinquiries@vedantabio.com

CONTACT

Steven Shiff, MD

857-706-1427

Consortium02-ctinquiries@vedantabio.com

CONTACT